Home >> Tag Archives: Beckman Coulter Life Sciences—

Tag Archives: Beckman Coulter Life Sciences—

Antibody panels for rare event detection, 11/17

November 2017—Beckman Coulter Life Sciences has introduced DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB).

Read More »

DuraClone RE antibody panels

Sept. 29, 2017—Beckman Coulter Life Sciences introduced its DuraClone RE antibody panels for the detection of rare, abnormal events in blood disorders. The panels provide tools to study low frequency populations of either abnormal CD5+ B cells (RE CLB), abnormal plasma cells (RE PC), or abnormal B progenitor cells (RE ALB). The three standardized, preformulated DuraClone RE kits, for research ...

Read More »

FDA-cleared IVD leukemia and lymphoma reagents

July 19, 2017—Beckman Coulter Life Sciences received FDA regulatory clearance, through the de novo process, to market its ClearLLab reagents for in vitro diagnostic use. The ClearLLab reagents deliver the first preformulated IVD antibody cocktails for leukemia and lymphoma immunophenotyping in the clinical laboratory. According to a June 29, 2017, news release from the FDA, the test “provides consistent results ...

Read More »
X